Kezar Life Sciences, Inc. (KZR) News
Filter KZR News Items
KZR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest KZR News From Around the Web
Below are the latest news stories about KEZAR LIFE SCIENCES INC that investors may wish to consider to help them evaluate KZR as an investment opportunity.
Kezar struck again with second FDA holdKezar dropped the programme investigating zetomipzomib in lupus after the first hold in October. |
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateSOUTH SAN FRANCISCO, Calif., November 12, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. |
Kezar Life Sciences Announces 1-for-10 Reverse Stock SplitSOUTH SAN FRANCISCO, Calif., October 28, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of one-for-ten (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 5:00 p.m. Eastern Time on October 29, 2024 (the "Effective Time"). The Co |
Kezar Life Sciences discontinues lupus nephritis programme after fatalitiesKezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths. |
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis StudyOn Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active lupus nephritis (LN) and focus clinical development efforts on zetomipzomib in autoimmune hepatitis (AIH). Last week, the FDA placed a clinical hold on the company’s zetomipzomib Investigational New Drug (IND) application for LN following a review of emerging safety data, including an assessment of four Grade 5 (fatal or death) serious adverse events (SAEs) that occurred du |
Kezar Life Sciences Rejects Concentra Biosciences Takeover Bid, Adopts Rights PlanKezar Life Sciences Rejects Concentra Biosciences Takeover Bid, Adopts Rights Plan |
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights PlanSOUTH SAN FRANCISCO, Calif., October 17, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the "Board") has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC ("Concentra") to acquire all of the outstanding shares of common stock of Kezar for cash consideration o |
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE UpdateSOUTH SAN FRANCISCO, Calif., October 17, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced key clinical development updates. |
What Makes Kezar Life Sciences (KZR) a New Buy StockKezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition ProposalSOUTH SAN FRANCISCO, Calif., October 10, 2024--Kezar Life Sciences, Inc. ("Kezar" or the "Company") (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it has received an unsolicited, non-binding proposal from Concentra Biosciences, LLC ("Concentra"), a Delaware limited liability company, to acquire all of the outstanding shares of common stock of Kezar for cash consideration of $1.10 per s |